Page last updated: 2024-08-24

plerixafor and Cancer, Second Primary

plerixafor has been researched along with Cancer, Second Primary in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Apperley, J; Blaise, D; Browne, P; Garderet, L; Iacobelli, S; Isaksson, C; Kobbe, G; Koster, L; Krejci, M; Kröger, N; Lenhoff, S; Ljungman, P; Morris, C; Muñiz, SG; Reményi, P; Russell, NH; Sahebi, F; Sanchez, JF; Sbianchi, G; Schaap, N; Scheid, C; Schönland, S; Trneny, M; Wiktor-Jedrzejczak, W; Wilson, KMO; Yakoub-Agha, I	1
Abidi, MH; Abrams, J; Al-Kadhimi, Z; Ayash, L; Deol, A; Lum, LG; Masood, A; Ratanatharathorn, V; Uberti, JP	1

Trials

1 trial(s) available for plerixafor and Cancer, Second Primary

Article	Year
Long-term follow up of patients proceeding to transplant using plerixafor mobilized stem cells and incidence of secondary myelodysplastic syndrome/AML. Bone marrow transplantation, 2013, Volume: 48, Issue:8 Topics: Adult; Aged; Benzylamines; Compassionate Use Trials; Cyclams; Female; Follow-Up Studies; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Incidence; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Survival Analysis; Treatment Outcome; Young Adult	2013

Article

Year

Long-term follow up of patients proceeding to transplant using plerixafor mobilized stem cells and incidence of secondary myelodysplastic syndrome/AML.

Bone marrow transplantation, 2013, Volume: 48, Issue:8

Topics: Adult; Aged; Benzylamines; Compassionate Use Trials; Cyclams; Female; Follow-Up Studies; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Incidence; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Survival Analysis; Treatment Outcome; Young Adult

2013

Other Studies

1 other study(ies) available for plerixafor and Cancer, Second Primary

Article	Year
Incidence of Second Primary Malignancies after Autologous Transplantation for Multiple Myeloma in the Era of Novel Agents. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2018, Volume: 24, Issue:5 Topics: Adult; Age Factors; Aged; Benzylamines; Cyclams; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Incidence; Male; Middle Aged; Multiple Myeloma; Neoplasms, Second Primary; Prospective Studies; Transplantation, Autologous; Young Adult	2018

Article

Year

Incidence of Second Primary Malignancies after Autologous Transplantation for Multiple Myeloma in the Era of Novel Agents.

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2018, Volume: 24, Issue:5

Topics: Adult; Age Factors; Aged; Benzylamines; Cyclams; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Incidence; Male; Middle Aged; Multiple Myeloma; Neoplasms, Second Primary; Prospective Studies; Transplantation, Autologous; Young Adult

2018